We help you to harness the power of biophysics to drug even the most challenging of targets. Whether it is an elusive transcription factor, a membrane protein or a protein-protein interaction motif, we have experience in developing leads against all of these and many other target classes.
Illarion is a research service provider specializing in the application of biophysical methods in early drug discovery. We focus on delivering screening assays and affinity determination methods that align with the throughput and timeline expectations of our customers.
Illarion was founded in 2026 by Reto Walser. Prior to that Reto worked as a biophysicist at AstraZeneca and Astex Pharmaceuticals in Cambridge (UK), two world renowned leaders in the application of biophysics to the drug discovery process.
Find better medicines faster! We are focused on developing and employing innovative biophysical technologies to address critical challenges in the field of early drug discovery. Our mission is to revolutionize how we go about finding and characterizing hits against novel targets for indications with unmet medical need.
Our dedication and expertise enables our customers in their journeys towards the clinic.
Biophysics-powered discovery solutions tailored to your target and modality.
Custom biophysical assays to get your target HTS-ready. We have extensive experience with transcription factors, GPCRs, ion channels, PPIs, RNA, and many other targets and develop the highest quality assays guided by rigorous QC metrics.
Automated compound screening at scale using the most sensitive biophysical methods and instruments combined with acoustic dispensing, plate analytics, and robust tracking of quality metrics across plates and screens.
Data analysis and hit calling powered by information-rich biophysical datasets and cheminformatics, delivering quality hits for your chemistry team to focus on.
Performant biophysical assays help you understand the structure-activity-relationship (SAR) of your hit matter. Explore the chemical space around your hits in record time with SAR-by-catalogue and array/library synthesis.
Iterative SAR support, potency & selectivity profiling, anti-target panels, and physico-chemical property monitoring. We ensure our assays continue to deliver mission-critical data to your projects up to candidate selection.
Bring an external perspective of an industry-experienced biophysicist to your projects. Access our expertise on biophysics-related questions ranging from target selection & tractability to screening and lead optimization.
Proven platforms, automated workflows, and analytics that deliver high-quality data at speed.
Proprietary automated data processing software delivering data to progress your projects and beyond. Whether it is in our own ML-ready format or a customer-specified format, we ensure the data we generate for you fits into your infrastructure to deliver value now and in the future.
DSF, SPR, NMR, ITC allow for direct-binding screening and characterizing binding affinities, kinetics and mechanisms for challenging targets with confidence.
Park Innovaare is located right next to the Paul Scherrer Institute (PSI), home to the Swiss Light Source (SLS) and the Swiss Free Electron Laser (SwissFEL) about half-way between the Swiss hubs of Basel and Zurich.
Want to find out more? Follow these links to Park Innovaare and the PSI.
